Predictive Oncology Inc（POAI）股票分析

$5.950

+0.030 (+0.51%)收盤時

Loading chart…

High: 6.000
Open: 5.950
VWAP: 5.78
Vol: 52.55K
Mkt Cap: 4.27M
Low: 5.400
Amount: 303.90K
EV/EBITDA, TTM: 0.24

Axe Compute Inc., formerly Predictive Oncology Inc., is engaged in using artificial intelligence (AI) and machine learning to expedite early drug discovery and enable drug development for the benefit of cancer patients worldwide. The Company’s scientifically validated AI platform, PEDAL, is able to predict with 92% accuracy when a tumor sample responds to a certain drug compound, allowing for a more informed selection of drug/tumor type combinations for subsequent in-vitro testing. Through AI, it uses its proprietary biobank of 150,000+ cancer tumor samples, categorized by patient type, against drug compounds to help the drug discovery process and increase the probability of drug development. The Company offers a suite of solutions for oncology drug development from early discovery to clinical trials.

predictive-oncology.com

估值指標

The current forward P/E ratio for Predictive Oncology Inc (POAI) is -10.57, compared to its 5-year average forward P/E of -3.61.

Forward P/E

Undervalued

5Y Average P/E

-3.61

Current P/E

-10.57

高估

-0.01

低估

-7.21

Forward EV/EBITDA

Fair

5Y Average EV/EBITDA

-0.65

Current EV/EBITDA

0.24

高估

1.56

低估

-2.85

Forward P/S

Fair

5Y Average P/S

7.14

Current P/S

1.17

高估

17.45

低估

-3.18

事件時間軸

2025-12-12 (ET)

08:10:00

Axe Compute Renames to Axe Compute Inc. and Will Trade on Nasdaq as AGPU on December 12, 2025

2025-10-14 (ET)

08:08:04

Predictive Oncology Reveals New Appointments to Leadership Team and Board

2025-09-29 (ET)

09:21:55

Predictive Oncology Sets Pricing for Private Placements to Launch Digital Asset Treasury

2025-09-25 (ET)

08:12:08

Predictive Oncology Declares 1-for-15 Reverse Stock Split

2025-09-04 (ET)

09:10:18

Predictive Oncology and Every Cure Form Strategic Partnership

Show More Events

資訊

POAI FAQ — answered by Alphio AI

Axe Compute Inc., formerly Predictive Oncology Inc., is engaged in using artificial intelligence (AI) and machine learning to expedite early drug discovery and enable drug development for the benefit of cancer patients worldwide. The Company’s scientifically validated AI platform, PEDAL, is able to predict with 92% accuracy when a tumor sample responds to a certain drug compound, allowing for a more informed selection of drug/tumor type combinations for subsequent in-vitro testing. Through AI, it uses its proprietary biobank of 150,000+ cancer tumor samples, categorized by patient type, against drug compounds to help the drug discovery process and increase the probability of drug development. The Company offers a suite of solutions for oncology drug development from early discovery to clinical trials. It operates in the Healthcare sector (ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUP industry).

本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。